Arcellx Inc. (ACLX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Arcellx Inc. (ACLX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

64.58

-2.78 (-4.13%)

At close: Jan 14, 2025, 3:59 PM

64.65

0.11%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	26.25
Market Cap	3.49B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.69
PE Ratio (ttm)	-93.59
Forward PE	n/a
Analyst	Buy

Ask	94.65
Volume	611,963
Avg. Volume (20D)	614,472
Open	68.06
Previous Close	67.36
Day's Range	64.39 - 68.92
52-Week Range	47.88 - 107.37
Beta	undefined

About ACLX

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 4, 2022

Employees 130

Stock Exchange NASDAQ

Ticker Symbol ACLX

Website https://arcellx.com

Analyst Forecast

According to 13 analyst ratings, the average rating for ACLX stock is "Buy." The 12-month stock price forecast is $114, which is an increase of 76.53% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Arcellx Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $25.47M, reflecting a -59.67% YoY shrinking and earnings per share of -0.48, making a -214.29% decrease YoY.

Why Price Moved

2 months ago · Source

+0.79%

Acrellx shares are trading lower after the company... Unlock content with Pro Subscription

5 months ago · Source

+12.31%

Arcellx shares are trading higher after the company reported better-than-expected Q2 financial results.

News

3 weeks ago · zacks.com

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

1 month ago · investors.com

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma.

1 month ago · benzinga.com

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).

1 month ago · businesswire.com

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...

2 months ago · zacks.com

Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice

Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago · zacks.com

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?

Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.

2 months ago · zacks.com

Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago.

2 months ago · zacks.com

Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa...